Prosecution Insights
Last updated: October 01, 2026
Application No. 17/974,131

EXPANDABLE INTRODUCER SHEATH FOR MEDICAL DEVICE

Final Rejection §102
Filed
Oct 26, 2022
Priority
Oct 28, 2021 — provisional 63/272,951
Examiner
WOLF, MEGAN YARNALL
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Abiomed Inc.
OA Round
2 (Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
376 granted / 616 resolved
-9.0% vs TC avg
Strong +39% interview lift
Without
With
+39.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
26 currently pending
Career history
650
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
40.8%
+0.8% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 616 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant's arguments filed 7/2/2026 have been considered but they are moot in view of the new grounds of rejection necessitated by the amendments. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4, 6, 8-13, 15, and 17-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Krolik et al. US 2007/0055358 (hereafter referred to as Krolik; cited by the examiner in the previous office action). Regarding claims 1 and 10, Krolik discloses an expandable sheath (fig.7) comprising: a tubular frame 140 (140 is a stent and stents are tubular) extending along a longitudinal axis 146 from a proximal end 144 to distal end 142, the tubular frame comprising: a plurality of radial expansion bands 149a and 149b, each radial expansion band at least partially extending around a circumference of the tubular frame, each radial expansion band comprising a band strut (considered the strut material of each band), each band strut comprising a plurality of end portions 109, and a plurality of connecting bridges 111, wherein each connecting bridge couples an end portion of the band strut of one radial expansion band to an end portion of the band strut of an adjacent radial expansion band (fig.7 shows each connecting bridge 111 couples adjacent bands), wherein the radial expansion bands and connecting bridges are formed by laser cutting the tubular frame (while this is a product-by-process claim limitation and given little patentable weight as discussed in MPEP 2113, pars.161 and 216 disclose laser cutting which is conventional), and wherein each end portion of the plurality of end portions of at least one band strut of at least one radial expansion band of the plurality of radial expansion bands connects to a connecting bridge of the plurality of connecting bridges (fig.7 shows every end portion 109 is directly connected to a connecting bridge), and a coating formed over at least an exterior of the tubular frame (pars. 163-165 disclose an exterior coating on any embodiment). Regarding claims 2 and 11, see fig.7 for the bands 149 alternating with the connecting bridges 111 along the longitudinal axis. Regarding claims 3 and 12, see fig.7 for bands 149 defining a zig-zag pattern around the circumference of the tubular frame. Regarding claims 4 and 13, see fig.7 for bands extending substantially perpendicularly to the longitudinal axis. Regarding claims 6, 9, 15, and 18, see fig.7 for continuous circumferential bands 149a, 149b. Regarding claims 8 and 17, see fig.7 which shows each connecting bridge 111 comprises portions capable of interfering with one another when the tubular frame is compressed along the longitudinal axis. The location and shape of the connecting bridges of Krolik are the same as the instant application. Therefore at least the legs of each bridge can interfere with another upon enough compressive force. Regarding claim 19, see fig.7 for each end portion 109 being a bent end portion wherein the plurality of bent end portions comprises first and second bent end portions (considered the peaks and valleys) which are connected by straight portions 108 (fig.7 shows each band 149a, 149b comprises alternating bent portions 109 and straight portions 108 forming the zig-zag pattern). Claims 1-3, 5, 6, 8-12, 14, 15, and 17-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ma et al. CN 1605366 A (hereafter referred to as Ma; cited in IDS; refer to the attached translation for passages referenced herein). Regarding claims 1 and 10, Ma discloses an expandable sheath comprising: a tubular frame extending along a longitudinal axis from a proximal end to distal end (fig.1 shows the stent laid flat as discloses in the middle of page 4 of the translation; stents are tubular), the tubular frame comprising: a plurality of radial expansion bands 2 (the oblique bands 2), each radial expansion band at least partially extending around a circumference of the tubular frame (fig.1), each radial expansion band comprising a band strut (considered the strut material of each band), each band strut comprising a plurality of end portions (considered the peaks and valleys of each band), and a plurality of connecting bridges 3, wherein each connecting bridge couples an end portion of the band strut of one radial expansion band to an end portion of the band strut of an adjacent radial expansion band (fig.1), and wherein each end portion of the plurality of end portions of at least one band strut of at least one radial expansion band of the plurality of radial expansion bands connects to a connecting bridge of the plurality of connecting bridges (fig.1 shows every bent end portion of the bands, not at the ends, are directly connected to a connecting bridge), and a coating formed over at least an exterior of the tubular frame (see translation page 3 par.7 which discloses the outer surface of the stent comprises grooves or blind holes that are coated). Regarding the limitation “wherein the radial expansion bands and connecting bridges are formed by laser cutting the tubular frame”, this is a product-by-process claim limitation and given little patentable weight as discussed in MPEP 2113. The final product of Ma is the same as the claimed stent structure and the stent being formed by laser cutting does not distinguish over the one-piece stent of Ma. Regarding claims 2 and 11, see fig.1 for the bands 2 alternating with the connecting bridges 3 along the longitudinal axis. Regarding claims 3 and 12, see fig.1 for bands defining a zig-zag pattern around the circumference of the tubular frame. Regarding claims 5 and 14, see fig.1 for bands extending obliquely to the longitudinal axis. Regarding claims 6, 9, 15, and 18, see fig.1 for continuous circumferential bands 2. Regarding claims 8 and 17, see fig.1 which shows each connecting bridge 3 comprises portions capable of interfering with one another when the tubular frame is compressed along the longitudinal axis. The location and shape of the connecting bridges of Ma are the same as the instant application. Therefore at least the legs of each bridge can interfere with another upon enough compressive force. Regarding claim 19, see fig.1 for each end portion being a bent end portion wherein the plurality of bent end portions comprises first and second bent end portions (considered the peaks and valleys) which are connected by straight portions (fig.1 shows each band 2 comprises alternating bent portions and straight portions forming the zig-zag pattern). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kveen et al. US 2003/0050690 discloses a stent comprising a plurality of obliquely angled radial expansion bands wherein each bent end portion of the bands is directly connected to a connecting bridge. Gregovich US 2005/0187606, Nguyen et al. US 2016/0310270, and Arbefeuille et al. US 2020/0246165 each disclose a stent comprising a plurality of radial expansion bands wherein at least one expansion band comprises each bent end portion of the band is directly connected to a connecting bridge. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGAN Y WOLF whose telephone number is (571)270-3071. The examiner can normally be reached Mon-Fri 8am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at (571)272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGAN Y WOLF/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Oct 26, 2022
Application Filed
Dec 19, 2024
Response after Non-Final Action
Apr 02, 2026
Non-Final Rejection mailed — §102
Jul 02, 2026
Response Filed
Sep 11, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746126
IMPLANT FOR FUSING AT LEAST TWO BONE COMPONENTS AND METHOD OF FUSING BONE COMPONENTS USING THE IMPLANT
5y 7m to grant Granted Sep 29, 2026
Patent 12746127
SLEEVE AUGMENT DEVICE FOR AN ARTICULATED JOINT
3y 1m to grant Granted Sep 29, 2026
Patent 12728012
IMPLANTABLE COMPONENT WITH IMPROVED ANCHORING MEANS FOR ANKLE PROSTHESIS AND ANKLE PROSTHESIS COMPRISING SUCH A COMPONENT
5y 7m to grant Granted Sep 08, 2026
Patent 12714569
Hip Joint Device and Method
4y 1m to grant Granted Aug 25, 2026
Patent 12702546
PROSTHETIC HEART VALVE LEAFLET ASSEMBLIES AND METHODS
4y 3m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+39.1%)
3y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 616 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month